Luteal phase support in intrauterine insemination cycles: a prospective randomized study of 300 mg versus 600 mg intravaginal progesterone tablet

Biberoglu E. H., Tanrikulu F., ERDEM M., ERDEM A., Biberoglu K. O.

GYNECOLOGICAL ENDOCRINOLOGY, cilt.32, sa.1, ss.55-57, 2016 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 32 Sayı: 1
  • Basım Tarihi: 2016
  • Doi Numarası: 10.3109/09513590.2015.1077382
  • Dergi Adı: GYNECOLOGICAL ENDOCRINOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.55-57
  • Anahtar Kelimeler: Controlled ovarian stimulation, corpus luteum deficiency, fecundability rate, ongoing pregnancy rate, unexplained infertility, HUMAN MENOPAUSAL GONADOTROPIN, VAGINAL PROGESTERONE, OVULATION INDUCTION, PREGNANCY RATES, IVF CYCLES, GEL, METAANALYSIS, IMPACT, WOMEN, HCG
  • Gazi Üniversitesi Adresli: Evet

Özet

Vaginal progesterone (P) has been suggested to be used for luteal phase support (LPS) in controlled ovarian stimulation (COH)-intrauterine insemination (IUI) cycles, however, no concensus exists about the best P dose. Therefore, considering the fecundability rate as the primary end point, our main objective was to find the optimal dose of P in COH-IUI cycles, comparing the two groups of women, each of which comprised of 100 women either on 300mg or 600mg of intravaginal P tablets, in a prospective randomized study design. The mean age of the women, duration of infertility, basal and day of hCG injection hormone levels in the female and sperm parameters were similar in the two study groups. Also, duration and dose of gonadotropin given, number of follicles, endometrial thickness, the total, ongoing and multiple pregnancy rates were comparable in both groups. We, therefore, claim that 300mg of intravaginal micronized P should be the maximum dose of LPS in IUI cycles.